TY - JOUR
T1 - Ethylene vinyl alcohol copolymer (Onyx) Embolization for acute hemorrhage
T2 - A systematic review of peripheral applications
AU - Kolber, Marcin K.
AU - Shukla, Pratik A.
AU - Kumar, Abhishek
AU - Silberzweig, James E.
N1 - Publisher Copyright:
© 2015 SIR.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Purpose To evaluate the endovascular use of ethylene vinyl alcohol (EVOH) copolymer (Onyx; ev3 Endovascular, Inc, Plymouth, Minnesota) for the treatment of acute peripheral nonneurologic hemorrhage. Materials and Methods MEDLINE and PubMed databases were searched for articles published in English from 1946 to August 2014 describing patients treated for hemorrhage with EVOH copolymer outside of its usual neurovascular applications. Additional cases were collected from the bibliographies of relevant articles. Full-text articles were obtained. Demographic data, clinical presentation, underlying etiology, culprit vessel, endovascular treatment, outcomes, and follow-up times were obtained. Results The literature search yielded 19 relevant articles. Cases of 131 patients (87 men, 44 women; mean age, 61 y ± 19.2) describing the treatment of 151 lesions were reviewed. The most common categories of arterial lesions were gastrointestinal (n = 53) and bronchial (n = 40) in origin. In 14 cases, EVOH copolymer was employed after failure or rebleeding following the use of a different embolic agent. Average follow-up time was 12.0 months. EVOH copolymer was the sole embolic agent used in 105 patients. Rebleeding after treatment with EVOH copolymer occurred in 10 patients. There were 2 technical failures. One patient died of multiorgan failure in the setting of persistent hemoptysis. Complications included 2 nerve injuries and 2 minor strokes. Conclusions Embolization of acute hemorrhage in the peripheral vasculature was safe and effective with EVOH copolymer.
AB - Purpose To evaluate the endovascular use of ethylene vinyl alcohol (EVOH) copolymer (Onyx; ev3 Endovascular, Inc, Plymouth, Minnesota) for the treatment of acute peripheral nonneurologic hemorrhage. Materials and Methods MEDLINE and PubMed databases were searched for articles published in English from 1946 to August 2014 describing patients treated for hemorrhage with EVOH copolymer outside of its usual neurovascular applications. Additional cases were collected from the bibliographies of relevant articles. Full-text articles were obtained. Demographic data, clinical presentation, underlying etiology, culprit vessel, endovascular treatment, outcomes, and follow-up times were obtained. Results The literature search yielded 19 relevant articles. Cases of 131 patients (87 men, 44 women; mean age, 61 y ± 19.2) describing the treatment of 151 lesions were reviewed. The most common categories of arterial lesions were gastrointestinal (n = 53) and bronchial (n = 40) in origin. In 14 cases, EVOH copolymer was employed after failure or rebleeding following the use of a different embolic agent. Average follow-up time was 12.0 months. EVOH copolymer was the sole embolic agent used in 105 patients. Rebleeding after treatment with EVOH copolymer occurred in 10 patients. There were 2 technical failures. One patient died of multiorgan failure in the setting of persistent hemoptysis. Complications included 2 nerve injuries and 2 minor strokes. Conclusions Embolization of acute hemorrhage in the peripheral vasculature was safe and effective with EVOH copolymer.
UR - http://www.scopus.com/inward/record.url?scp=84930382276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930382276&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2015.02.025
DO - 10.1016/j.jvir.2015.02.025
M3 - Article
C2 - 25866238
AN - SCOPUS:84930382276
SN - 1051-0443
VL - 26
SP - 809
EP - 815
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 6
ER -